🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

So excited to be in Mozambique with @NCICastle collaborating with CISPOC - INS - DPCM UEM - Moçambique and MD Anderson Cancer Center team to launch the PHIL study - a randomized trial of LEEP vs. Thermal Ablation in WLWH Mila Pontremoli Salcedo Melissa S. Lopez liz chiao Jose A. Jeronimo #EndCancer

Among patients undergoing gynecologic cancer surgery, adding metronidazole to cefazolin for antibiotic prophylaxis was associated with a reduced rate of surgical site infection. 👏👏👏 AJOG sciencedirect.com/science/articl… Anne Knisely, MD Jolyn Taylor Kathleen Schmeler MD MD Anderson Cancer Center

Dear members of Meshal, a question came up during our journal club and I cannot find the answer. Can someone please help? Why did investigators in the RUBY trial pick 3 years of Dostarlimab maintenance? Is there a biologic explanation? Matt Powell #endometrialcancer

Adding cisplatin to radiation doesn't improve progression-free survival for localized recurrent #endometrialcancer but does increase treatment-related toxicity. Radiation remains standard of care. ascopubs.org/doi/10.1200/JC… Journal of Clinical Oncology Ann Klopp David Scott Miller #gyncsm #gynonc

Ever wonder why your insurer charges a copay for statins (and other high-value meds)? Don’t they want to prevent heart attacks, strokes, etc? Copays never made sense to me. In this new paper in QJE, we show copays kill. 🧵 tinyurl.com/nhk4v93f

The rate of new #OvarianCancer cases fell by 2.7% each year from 2012 – 2021 and the death rate fell by 2.4% each year from 2013 – 2022. Visit our Cancer Stat Facts sheet to learn more: buff.ly/2ITyl21 #GynCSM #WorldOvarianCancerDay

Dr. Frumovitz has made an incredible impact in #gynonc, both as a gifted educator & researcher. Consider a gift to honor his contributions to our field & support his research in the treatment of rare #gyn cancers. mdanderson.donordrive.com/index.cfm?fuse… Michael Frumovitz MD Anderson Cancer Center SGO

#Small bite fascial closure reduces #incisional hernia rates in #GynOncology patients by Shitanshu Uppal Alli 📄 bit.ly/45hpH5D @umichMedicine Pedro T Ramirez Arthur_HC_Hsu Aarthi S Jayraj Andreina Fernandes IGCS ESGO European Network of Young Gynae Oncologists OncoAlert IJGC Fellows SoMe4GynOnc

From medical enigma to a roadmap for recovery, one OHSU News patient's life-altering journey through a rare skin, musculature condition and stage 3 cancer. This is Kathy's remarkable story: bit.ly/4b2Exhx

Rates of new #UterineCancer cases increased by 0.7% each year from 2012 to 2021. The death rate from uterine cancer increased by 1.5% each year from 2013 to 2022. Visit our Cancer Stat Facts sheet to learn more: buff.ly/2YXE2S4 #GynCSM

People with advanced #EndometrialCancer now have new FDA-approved treatment options: pembrolizumab and durvalumab, paired with chemotherapy, for tumors with a genetic change called mismatch repair deficiency. go.nih.gov/Qmz5ojG

Nice presentation of FIGO 2023 #endometrialcancer staging. From a review in NatureRevClinOncol. Jeffrey How nature.com/articles/s4157…

Surgical video reviewing uterine transposition, patient selection, & postoperative management.👏👏👏 #crcsm #ayacsm #gynonc #gyncsm Mario M. Leitao, Jr Jenny Mueller MD Memorial Sloan Kettering Cancer Center Annals of Surgical Oncology link.springer.com/article/10.124…

Excited to represent SGO FdtnForWomensCancer as Social Media Ambassador for our 2025 Annual #SGOMtg! ⏰ Abstract submission deadline is approaching quickly Sept 27th! We will Multiply Your Impact through our exciting program and social media!💥Join us in Seattle! #AM25IMPACT #gyncsm

Today at the @RivkinCenter AACR Ovarian Cancer Research Symposium Moffitt’s Karen Lu, MD (Karen Lu) co-chairs the Prevention, Early Detection, & Interception session. Check out her video to learn more! ⏰: 9/20 -4:50 p.m. PDT 📍: Washington Ballroom Learn more ➡️

Randomized trial of patients with high-risk #endometrialcancer (n=1095) did not find improvement in disease-free survival from adding #pembrolizumab to postoperative adjuvant treatment (HR 1.02, 95% CI 0.79-1.32, p=.57). Pembrolizumab was associated with better survival (HR 0.31,

Multicenter retrospective study of patients with early #cervicalcancer (n=675) finds assessment of tumor size by preoperative exam and/or MRI have good concordance (>80%) with surgical pathology measurements. #gyncsm Teresa Lucia Pan, MD Pedro T Ramirez IJGC